A SECOND PHASE III MULTICENTER PLACEBO CONTROLLED STUDY OF 2 DOSAGES OF MODIFIED RELEASE TAMSULOSIN IN PATIENTS WITH SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Urology
Reference8 articles.
1. Pharmacological Receptors in the Prostate
2. Alpha1-adrenoceptors in human prostate: Characterization and binding characteristics of alpha1-antagonists
3. A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Role of alpha blockers in treating obstructive uropathy;Urologie pro praxi;2021-01-06
2. Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia;BJU International;2005-08
3. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha1-adrenoceptor antagonists;BJU International;2005-06
4. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia;BJU International;2005-05
5. Pharmakologische Therapie des benignen Prostatasyndroms;Pharmakotherapie in der Urologie;2005
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3